Fabián Pitoia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fabián Pitoia has a total of 430 co-authors. Here are the top co-authors by number of shared publications:
Hugo Niepomniszcze
University of Buenos Aires
22 shared publications- Erika Abelleira
Division of Endocrinology, Hospital de Clínicas, University of Buenos Aires, Buenos Aires, Argentina
19 shared publications Erika Abelleira
Division of Endocrinology, Hospital de Clínicas José de San Martin, University of Buenos Aires, Buenos Aires, Argentina
16 shared publicationsFernanda Bueno
Hospital de Clínicas José de San Martín: Hospital de Clinicas Jose de San Martin
16 shared publications- Anabella Smulever
Instituto de Investigaciones Medicas Alfredo Lanari, University of Buenos Aires, Buenos Aires, Argentina
14 shared publications - Inés Califano
Department of Endocrinology, Instituto de Oncologia AH Roffo, University of Buenos Aires, Buenos Aires, Argentina
14 shared publications
Latest Publications
- 4 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
International Initiative on a Refined Staging System for Medullary Thyroid Cancer: A Multinational Multicenter Study
PURPOSE: To refine the suboptimal prognostic discrimination of the American Joint Committee on Cancer (AJCC) 8th edition TNM (TNM-8) staging system for medullary thyroid carcinoma (MTC). METHODS: This retrospective study enrolled patients with MTC from 43 centers across 15 countries under the framework of the International Medullary Thyroid Cancer Staging Consortium (IMTCSC). Pooled data were analyzed with disease-specific survival as the primary end point. With M1 disease fixed in stage IVC, we redefined the schema for stages I to IVB in M0 patients. Using exhaustive enumeration, all possible TN combinations were fitted into multivariable Cox models, with the lowest Akaike information criterion (AIC) defining the proposed system. Prognostic discrimination was assessed using adjusted hazard ratios (aHRs) and the concordance index (C-index). RESULTS: The IMTCSC cohort included 2,573 patients with MTC (female-to-male ratio: 1.25; median age 52 years [IQR, 41-62]; median follow-up 76.3 months [IQR, 37.3-121.0]). Level VII metastasis correlated with poorer survival, supporting its upgrade to N1c. Exhaustive search of 116,284 admissible stage-grouping schemas identified the optimal model (lowest AIC) defining stages I to IVB: I (T1N0-N1a/T2N0), II (T1N1b/T2N1a/T3N0), III (T1N1c/T2N1b/T3N1a/T4aN0-N1a), IVA (T2N1c/T3N1b-N1c/T4aN1b), and IVB (T4aN1c/T4b any N). Compared with AJCC TNM-8 (stage I as reference; stage II aHR, 0.84, P = .652; stage III aHR, 1.48, P = .172; stage IV aHR, 7.95, P < .001), the proposed system showed a clearer monotonic increase in disease-specific death risk (stage II aHR 2.22; stage III aHR, 4.81; stage IV aHR 15.75; all P ≤ .001) and a higher C-index (0.892 v 0.856, P < .001), which was also evaluated in the SEER cohort (N = 1,909). CONCLUSION: The proposed MTC staging system confers an improved schema for prognostic stratification compared with AJCC TNM-8.
- 4 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
International Initiative on a Refined Staging System for Medullary Thyroid Cancer: A Multinational Multicenter Study
PURPOSE: To refine the suboptimal prognostic discrimination of the American Joint Committee on Cancer (AJCC) 8th edition TNM (TNM-8) staging system for medullary thyroid carcinoma (MTC). METHODS: This retrospective study enrolled patients with MTC from 43 centers across 15 countries under the framework of the International Medullary Thyroid Cancer Staging Consortium (IMTCSC). Pooled data were analyzed with disease-specific survival as the primary end point. With M1 disease fixed in stage IVC, we redefined the schema for stages I to IVB in M0 patients. Using exhaustive enumeration, all possible TN combinations were fitted into multivariable Cox models, with the lowest Akaike information criterion (AIC) defining the proposed system. Prognostic discrimination was assessed using adjusted hazard ratios (aHRs) and the concordance index (C-index). RESULTS: The IMTCSC cohort included 2,573 patients with MTC (female-to-male ratio: 1.25; median age 52 years [IQR, 41-62]; median follow-up 76.3 months [IQR, 37.3-121.0]). Level VII metastasis correlated with poorer survival, supporting its upgrade to N1c. Exhaustive search of 116,284 admissible stage-grouping schemas identified the optimal model (lowest AIC) defining stages I to IVB: I (T1N0-N1a/T2N0), II (T1N1b/T2N1a/T3N0), III (T1N1c/T2N1b/T3N1a/T4aN0-N1a), IVA (T2N1c/T3N1b-N1c/T4aN1b), and IVB (T4aN1c/T4b any N). Compared with AJCC TNM-8 (stage I as reference; stage II aHR, 0.84, P = .652; stage III aHR, 1.48, P = .172; stage IV aHR, 7.95, P < .001), the proposed system showed a clearer monotonic increase in disease-specific death risk (stage II aHR 2.22; stage III aHR, 4.81; stage IV aHR 15.75; all P ≤ .001) and a higher C-index (0.892 v 0.856, P < .001), which was also evaluated in the SEER cohort (N = 1,909). CONCLUSION: The proposed MTC staging system confers an improved schema for prognostic stratification compared with AJCC TNM-8.
- 16 September 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 302
Neoadjuvant therapy in thyroid cancer: an emerging approach
- 16 September 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 302
Neoadjuvant therapy in thyroid cancer: an emerging approach
- Open Access
- 10 August 2026
- Published by Asociacion Colombiana de Endocrinologia, Diabetes y Metabolismo in Revista Colombiana de Endocrinología, Diabetes & Metabolismo
- Vol. 13 (3)
Rediferenciación en el cáncer de tiroides refractario al yodo radiactivo: ¿es suficiente con restaurar la captación de yodo?
La refractariedad al yodo radiactivo (RAI) representa un punto de inflexión importante en la historia natural del cáncer diferenciado de tiroides (CDT). La pérdida de avidez por el yodo puede reflejar la supresión de la maquinaria molecular responsable del transporte y metabolismo del yodo, frecuentemente impulsada por la activación constitutiva de la vía MAPK. Por esta razón, la inhibición farmacológica de esta vía ha despertado un interés considerable como estrategia para restaurar la diferenciación tiroidea y, potencialmente, volver a hacer posible el tratamiento con RAI. La revisión sistemática y metaanálisis publicados en este número ofrecen una oportunidad valiosa para reconsiderar qué se ha logrado hasta ahora con las estrategias de rediferenciación y cuáles son las principales incertidumbres que persisten. En el presente metaanálisis, la inhibición de corta duración de la vía MAPK logró restaurar una captación detectable de RAI en el 62,3 % de los pacientes, aunque esta proporción disminuyó cuando se aplicó un umbral dosimétrico terapéutico más estricto. En los estudios prospectivos, y dependiendo del contexto molecular, el esquema terapéutico, la metodología de imagen y la definición utilizada para considerar exitosa la rediferenciación, la restauración de la captación de yodo ha oscilado aproximadamente entre el 60 % y más del 90 %. En el ensayo fase II MERAIODE, por ejemplo, se observó captación anormal en el 95 % de las gammagrafías posteriores al tratamiento con dabrafenib más trametinib en pacientes con CDT con mutación BRAF V600E. Sin embargo, restaurar la captación de yodo y restaurar la sensibilidad al RAI no son necesariamente equivalentes. Esta distinción constituye probablemente la cuestión central en torno a la rediferenciación en la actualidad. Las respuestas estructurales son consistentemente menos frecuentes que la recuperación de la avidez por el yodo. En los estudios prospectivos, las respuestas objetivas después de la administración posterior de RAI han sido variables y, en general, menos frecuentes que la restauración de la captación de yodo. En el ensayo MERAIODE, la tasa de respuesta parcial a los seis meses fue del 38 % en los tumores con mutación BRAF V600E y del 20 % en la cohorte con mutaciones en RAS.
- 10 August 2026
- Published by Asociacion Colombiana de Endocrinologia, Diabetes y Metabolismo in Revista Colombiana de Endocrinología, Diabetes & Metabolismo
- Vol. 13 (3)
Open AccessRediferenciación en el cáncer de tiroides refractario al yodo radiactivo: ¿es suficiente con restaurar la captación de yodo?
La refractariedad al yodo radiactivo (RAI) representa un punto de inflexión importante en la historia natural del cáncer diferenciado de tiroides (CDT). La pérdida de avidez por el yodo puede reflejar la supresión de la maquinaria molecular responsable del transporte y metabolismo del yodo, frecuentemente impulsada por la activación constitutiva de la vía MAPK. Por esta razón, la inhibición farmacológica de esta vía ha despertado un interés considerable como estrategia para restaurar la diferenciación tiroidea y, potencialmente, volver a hacer posible el tratamiento con RAI. La revisión sistemática y metaanálisis publicados en este número ofrecen una oportunidad valiosa para reconsiderar qué se ha logrado hasta ahora con las estrategias de rediferenciación y cuáles son las principales incertidumbres que persisten. En el presente metaanálisis, la inhibición de corta duración de la vía MAPK logró restaurar una captación detectable de RAI en el 62,3 % de los pacientes, aunque esta proporción disminuyó cuando se aplicó un umbral dosimétrico terapéutico más estricto. En los estudios prospectivos, y dependiendo del contexto molecular, el esquema terapéutico, la metodología de imagen y la definición utilizada para considerar exitosa la rediferenciación, la restauración de la captación de yodo ha oscilado aproximadamente entre el 60 % y más del 90 %. En el ensayo fase II MERAIODE, por ejemplo, se observó captación anormal en el 95 % de las gammagrafías posteriores al tratamiento con dabrafenib más trametinib en pacientes con CDT con mutación BRAF V600E. Sin embargo, restaurar la captación de yodo y restaurar la sensibilidad al RAI no son necesariamente equivalentes. Esta distinción constituye probablemente la cuestión central en torno a la rediferenciación en la actualidad. Las respuestas estructurales son consistentemente menos frecuentes que la recuperación de la avidez por el yodo. En los estudios prospectivos, las respuestas objetivas después de la administración posterior de RAI han sido variables y, en general, menos frecuentes que la restauración de la captación de yodo. En el ensayo MERAIODE, la tasa de respuesta parcial a los seis meses fue del 38 % en los tumores con mutación BRAF V600E y del 20 % en la cohorte con mutaciones en RAS.
- 3 August 2026
- Published by SAGE Publications in Thyroid®
- Vol. 36 (9) , 940-950
Prognostic Stratification of Brain Metastases from Nonanaplastic Follicular Cell–Derived Thyroid Carcinoma: Results of an International Multicenter Retrospective Study
Background: Brain metastases (BMs) from nonanaplastic follicular cell–derived thyroid carcinoma (hereinafter referred to as non-ATC) are rare and not well characterized, with limited evidence guiding treatment and prognostic stratification. We aimed to describe clinical features, treatment patterns, and outcomes of patients with BMs from non-ATC and to develop and validate a disease-specific prognostic score. Methods: This retrospective international multicenter study included adults with histologically confirmed non-ATC and radiologically documented BMs treated at 19 tertiary referral centers. Clinical, radiological, treatment, and outcome data were collected. Independent predictors of progression-free survival (PFS) and overall survival (OS) were analyzed using Cox regression, and variables identified were used to develop a disease-specific Graded Prognostic Assessment (non-ATC GPA), exploratorily assessed in an independent SEER cohort. Results: A total of 189 patients were included; median age at BM diagnosis was 59 years (interquartile range [IQR] 48–67). First-line BM treatments included stereotactic radiosurgery (27.0%), neurosurgery (23.8%), whole-brain radiotherapy (18.5%), and best supportive care (10.6%). Median PFS was 7.0 months (IQR: 2.9–22.4), and median OS was 15.0 months (IQR: 4.0–38.4). Independent predictors of shorter OS were age >75 years, Eastern Cooperative Oncology Group performance status ≥2, papillary histology, extracranial metastases, and ≥4 BM. The GPA stratified patients into four prognostic groups with median OS ranging from 72.6 months in the highest-score group to 3.7 months in the lowest. An exploratory SEER-based assessment showed survival differences across adapted prognostic groups ( p = 0.036), although this analysis was limited by the absence of all key GPA variables. Conclusions: BMs from non-ATC are associated with poor survival and marked prognostic heterogeneity. The proposed GPA may provide a useful framework for prognostic stratification, pending further validation in independent datasets to support individualized management.
- 3 August 2026
- Published by SAGE Publications in Thyroid®
- Vol. 36 (9) , 940-950
Prognostic Stratification of Brain Metastases from Nonanaplastic Follicular Cell–Derived Thyroid Carcinoma: Results of an International Multicenter Retrospective Study
Background: Brain metastases (BMs) from nonanaplastic follicular cell–derived thyroid carcinoma (hereinafter referred to as non-ATC) are rare and not well characterized, with limited evidence guiding treatment and prognostic stratification. We aimed to describe clinical features, treatment patterns, and outcomes of patients with BMs from non-ATC and to develop and validate a disease-specific prognostic score. Methods: This retrospective international multicenter study included adults with histologically confirmed non-ATC and radiologically documented BMs treated at 19 tertiary referral centers. Clinical, radiological, treatment, and outcome data were collected. Independent predictors of progression-free survival (PFS) and overall survival (OS) were analyzed using Cox regression, and variables identified were used to develop a disease-specific Graded Prognostic Assessment (non-ATC GPA), exploratorily assessed in an independent SEER cohort. Results: A total of 189 patients were included; median age at BM diagnosis was 59 years (interquartile range [IQR] 48–67). First-line BM treatments included stereotactic radiosurgery (27.0%), neurosurgery (23.8%), whole-brain radiotherapy (18.5%), and best supportive care (10.6%). Median PFS was 7.0 months (IQR: 2.9–22.4), and median OS was 15.0 months (IQR: 4.0–38.4). Independent predictors of shorter OS were age >75 years, Eastern Cooperative Oncology Group performance status ≥2, papillary histology, extracranial metastases, and ≥4 BM. The GPA stratified patients into four prognostic groups with median OS ranging from 72.6 months in the highest-score group to 3.7 months in the lowest. An exploratory SEER-based assessment showed survival differences across adapted prognostic groups ( p = 0.036), although this analysis was limited by the absence of all key GPA variables. Conclusions: BMs from non-ATC are associated with poor survival and marked prognostic heterogeneity. The proposed GPA may provide a useful framework for prognostic stratification, pending further validation in independent datasets to support individualized management.
- 15 July 2026
- Published by SAGE Publications in Thyroid®
- Vol. 36 (10) , 1148-1150
Letter to the editor: When Guidelines Meet Reality: Implementing the 2025 ATA Recommendations for Differentiated Thyroid Cancer in Limited-Resource Settings
- 15 July 2026
- Published by SAGE Publications in Thyroid®
- Vol. 36 (10) , 1148-1150
Letter to the editor: When Guidelines Meet Reality: Implementing the 2025 ATA Recommendations for Differentiated Thyroid Cancer in Limited-Resource Settings
- 13 July 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 229
Anaplastic thyroid carcinoma in Argentina: real-world diagnostic lags and treatment barriers
Purpose Anaplastic thyroid carcinoma (ATC) is an aggressive malignancy with high mortality. Approximately 50% harbor the BRAF V600E mutation, for which dabrafenib-trametinib (DT) has been associated with improved survival (OS). Prompt diagnosis and access to molecular testing and targeted therapy are critical for outcomes. We evaluated diagnostic and therapeutic barriers in ATC patients treated in Buenos Aires, Argentina. Methods This retrospective multicenter cohort study included 48 ATC patients from 11 centers in Buenos Aires (2019–2025). Initial diagnostic methods (IDMs) included fine-needle aspiration cytology (FNAC), core needle biopsy (CNB), surgical biopsy, or unsuspected diagnosis after thyroidectomy. We assessed diagnostic delay, BRAF testing, DT access, and OS. Results Median time from symptom onset to diagnosis was 3.16 months (IQR: 2–5.5). FNAC was the most frequent IDM (62%), but confirmed ATC in only 30%. Unsuspected ATC diagnosed in surgical specimens accounted for 29% of cases. BRAF testing was performed in 70% of patients, with 59% positivity, and a median turnaround of 7.5 days (IQR 4–29) from collection to result. Median time from diagnosis to DT initiation was 39 days (IQR 22–70). Only 40% of eligible BRAF-positive patients received DT. Median OS was 3.23 months (IQR 1.4–11.5). In an exploratory unadjusted analysis, DT-treated patients had longer OS (8.6 vs. 3.61 months; p = 0.037). Unsuspected ATC diagnosed after thyroidectomy and surgery were associated with longer OS. Conclusions Diagnostic delays and barriers to molecular testing and targeted therapy remain substantial. Optimizing diagnostic pathways, prioritizing representative tissue sampling, and improving timely access to molecular testing and DT may enable earlier treatment and better outcomes.
- 13 July 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 229
Anaplastic thyroid carcinoma in Argentina: real-world diagnostic lags and treatment barriers
Purpose Anaplastic thyroid carcinoma (ATC) is an aggressive malignancy with high mortality. Approximately 50% harbor the BRAF V600E mutation, for which dabrafenib-trametinib (DT) has been associated with improved survival (OS). Prompt diagnosis and access to molecular testing and targeted therapy are critical for outcomes. We evaluated diagnostic and therapeutic barriers in ATC patients treated in Buenos Aires, Argentina. Methods This retrospective multicenter cohort study included 48 ATC patients from 11 centers in Buenos Aires (2019–2025). Initial diagnostic methods (IDMs) included fine-needle aspiration cytology (FNAC), core needle biopsy (CNB), surgical biopsy, or unsuspected diagnosis after thyroidectomy. We assessed diagnostic delay, BRAF testing, DT access, and OS. Results Median time from symptom onset to diagnosis was 3.16 months (IQR: 2–5.5). FNAC was the most frequent IDM (62%), but confirmed ATC in only 30%. Unsuspected ATC diagnosed in surgical specimens accounted for 29% of cases. BRAF testing was performed in 70% of patients, with 59% positivity, and a median turnaround of 7.5 days (IQR 4–29) from collection to result. Median time from diagnosis to DT initiation was 39 days (IQR 22–70). Only 40% of eligible BRAF-positive patients received DT. Median OS was 3.23 months (IQR 1.4–11.5). In an exploratory unadjusted analysis, DT-treated patients had longer OS (8.6 vs. 3.61 months; p = 0.037). Unsuspected ATC diagnosed after thyroidectomy and surgery were associated with longer OS. Conclusions Diagnostic delays and barriers to molecular testing and targeted therapy remain substantial. Optimizing diagnostic pathways, prioritizing representative tissue sampling, and improving timely access to molecular testing and DT may enable earlier treatment and better outcomes.
- 10 July 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1)
Risk of recurrence in differentiated thyroid cancer: beyond baseline stratification
- 10 July 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1)
Risk of recurrence in differentiated thyroid cancer: beyond baseline stratification
- Open Access
- 1 January 2026
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 70 (5) , 1-21
Latin American Thyroid Society expert panel consensus on anaplastic thyroid cancer
Anaplastic thyroid cancer (ATC) is a highly aggressive histologic subtype of thyroid malignancy. Its rarity, rapidly progressive clinical course, along with limitations in health-care resources make management particularly challenging in Latin America. In recent years, substantial advances in the understanding of ATC biology have led to modifications in therapeutic strategies. This consensus aims to raise awareness and provide practical, evidence-based guidance for the diagnosis and management of ATC, summarizing current diagnostic and therapeutic advances while offering an accessible framework tailored to the Latin American context. A multidisciplinary panel of experts in endocrinology, surgery, oncology, pathology, and genetics from Latin American countries developed a series of recommendations. Each recommendation is accompanied by its rationale and supporting evidence, adapted to the regional context to facilitate implementation. All recommendations were reviewed and voted on through a non-anonymous process. Recommendation wording was pre-specified and linked to voting thresholds: “should” indicated unanimous agreement (100%); “is recommended” indicated ≥70% agreement; and “may be considered” was used when agreement was <70% and/or when applicability depended on local availability, feasibility, or patient-specific clinical context. The consensus includes 37 recommendations covering the initial approach, diagnosis, and management of locoregional and advanced disease. By integrating current evidence with expert consensus and accounting for regional resource variability, this document aims to harmonize clinical practice, support multidisciplinary care, and facilitate timely diagnosis and treatment. These recommendations may also serve as a foundation for future research initiatives and the development and updating of regional health policies for this highly lethal disease.
- 1 January 2026
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 70 (5) , 1-21
Open AccessLatin American Thyroid Society expert panel consensus on anaplastic thyroid cancer
Anaplastic thyroid cancer (ATC) is a highly aggressive histologic subtype of thyroid malignancy. Its rarity, rapidly progressive clinical course, along with limitations in health-care resources make management particularly challenging in Latin America. In recent years, substantial advances in the understanding of ATC biology have led to modifications in therapeutic strategies. This consensus aims to raise awareness and provide practical, evidence-based guidance for the diagnosis and management of ATC, summarizing current diagnostic and therapeutic advances while offering an accessible framework tailored to the Latin American context. A multidisciplinary panel of experts in endocrinology, surgery, oncology, pathology, and genetics from Latin American countries developed a series of recommendations. Each recommendation is accompanied by its rationale and supporting evidence, adapted to the regional context to facilitate implementation. All recommendations were reviewed and voted on through a non-anonymous process. Recommendation wording was pre-specified and linked to voting thresholds: “should” indicated unanimous agreement (100%); “is recommended” indicated ≥70% agreement; and “may be considered” was used when agreement was <70% and/or when applicability depended on local availability, feasibility, or patient-specific clinical context. The consensus includes 37 recommendations covering the initial approach, diagnosis, and management of locoregional and advanced disease. By integrating current evidence with expert consensus and accounting for regional resource variability, this document aims to harmonize clinical practice, support multidisciplinary care, and facilitate timely diagnosis and treatment. These recommendations may also serve as a foundation for future research initiatives and the development and updating of regional health policies for this highly lethal disease.
- 29 December 2025
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 17
Short-Term BRAF Inhibition with Dabrafenib induced redifferentiation in a subset of patients with BRAF V600E–Mutant papillary thyroid carcinoma
- 29 December 2025
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 17
Short-Term BRAF Inhibition with Dabrafenib induced redifferentiation in a subset of patients with BRAF V600E–Mutant papillary thyroid carcinoma
- 25 August 2025
- Published by SAGE Publications in Thyroid®
- Vol. 35 (10) , 1198-1201
Interobserver Agreement Among Thyroid Ultrasound Operators in Defining Thyroid Nodules as Subcapsular
Background: Ultrasound (US) examination is the pivotal test to assess the risk of cancer and the indication for fine needle aspiration cytology (FNAC) in thyroid nodules (TNs). The subcapsular location of a TN may strengthen the indication for FNAC as, in TN resulting malignant at cytology may favor surgery rather than active surveillance. However, the definition of a subcapsular TN remains unclear. This study aimed to evaluate the interobserver agreement (IOA) among thyroid US experts in classifying TNs as subcapsular or not. Methods: Twelve raters received an electronic link to a file containing static US images and were asked to assess 60 TNs for subcapsular location, blinded to all other TN characteristics. The overall IOA was calculated, and the TN US features were subsequently analyzed to evaluate their potential influence on interobserver variability. The raters had high or very high thyroid US experience. Two experienced operators preliminarily selected the case series and analyzed the findings. All cases were derived from patients undergoing surgery and histological diagnosis. The IOA was calculated according to Fleiss’ kappa, ranging from 0.0 (no agreement) to 1.0 (perfect agreement). Results: The overall IOA was fair (κ = 0.34), with a slightly better result in the subgroup of raters with higher experience (κ = 0.39). A higher IOA value (κ = 0.38) was observed in TNs of medium size. Following multiple sub-analyses, the highest κ value (0.46) was observed in the subgroup of TNs that were categorized as EU-TIRADS 5 and were smaller than 2 cm. Conclusions: The overall IOA among US experts when assessing TNs as subcapsular was unsatisfactory. A clear and standardized definition of subcapsular position is needed to improve clinical decision-making. Future guidelines should address this issue to ensure consistent assessment and management of subcapsular TNs.
- 25 August 2025
- Published by SAGE Publications in Thyroid®
- Vol. 35 (10) , 1198-1201
Interobserver Agreement Among Thyroid Ultrasound Operators in Defining Thyroid Nodules as Subcapsular
Background: Ultrasound (US) examination is the pivotal test to assess the risk of cancer and the indication for fine needle aspiration cytology (FNAC) in thyroid nodules (TNs). The subcapsular location of a TN may strengthen the indication for FNAC as, in TN resulting malignant at cytology may favor surgery rather than active surveillance. However, the definition of a subcapsular TN remains unclear. This study aimed to evaluate the interobserver agreement (IOA) among thyroid US experts in classifying TNs as subcapsular or not. Methods: Twelve raters received an electronic link to a file containing static US images and were asked to assess 60 TNs for subcapsular location, blinded to all other TN characteristics. The overall IOA was calculated, and the TN US features were subsequently analyzed to evaluate their potential influence on interobserver variability. The raters had high or very high thyroid US experience. Two experienced operators preliminarily selected the case series and analyzed the findings. All cases were derived from patients undergoing surgery and histological diagnosis. The IOA was calculated according to Fleiss’ kappa, ranging from 0.0 (no agreement) to 1.0 (perfect agreement). Results: The overall IOA was fair (κ = 0.34), with a slightly better result in the subgroup of raters with higher experience (κ = 0.39). A higher IOA value (κ = 0.38) was observed in TNs of medium size. Following multiple sub-analyses, the highest κ value (0.46) was observed in the subgroup of TNs that were categorized as EU-TIRADS 5 and were smaller than 2 cm. Conclusions: The overall IOA among US experts when assessing TNs as subcapsular was unsatisfactory. A clear and standardized definition of subcapsular position is needed to improve clinical decision-making. Future guidelines should address this issue to ensure consistent assessment and management of subcapsular TNs.